Organization
Northshore University Health System
5 abstracts
Abstract
Association between rare pathogenic variants in established cancer risk genes and the diagnosis of single and multiple common cancers: A UK Biobank study.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers and Department of Medicine, Duke University School of Medicine, Durham, NC, NorthShore University HealthSystem Research Institute, Evanston, IL,
Abstract
The contribution of rare and common genetic variants to risk of prostate cancer and second primary cancer after prostate in the UK Biobank.Org: Barbara Ann Karmanos Cancer Institute, Duke Cancer Institute and Department of Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Karmanos Cancer Institute, Wayne State University School of Medicine, Northshore University Health System,
Abstract
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.Org: University of Chicago, University of Chicago Medicine, Northshore University Health System, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Org: University of Chicago, Northshore University Health System, Froedtert & Medical College of Wisconsin, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.Org: Northshore University Health System, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Levine Cancer Institute, Atrium Health Carolinas Medical Center, Carolina Urologic Research Center,